ReviewBioengineered2022
Efficient remediation of antibiotic pollutants from the environment by innovative biochar: current updates and prospects.
Review in Bioengineered, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 40 citations in OpenAlex.
- Deciphering biochar-PGPR-plant synergies for sustainable soil rhizoremediation of organic pollutants.Archives of microbiology · 2026Review
- Biochar Innovations for Organic Pollutant Remediation in Contaminated Soils.Molecules (Basel, Switzerland) · 2026Review
- Modeling antimicrobial fate in the circular food system.Risk analysis : an official publication of the Society for Risk Analysis · 2025Article
- Biochar filtration of drug-resistant bacteria and active pharmaceutical ingredients to combat antimicrobial resistance.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increased antibiotic consumption and their improper management led to serious antibiotic pollution and its exposure to the environment develops multidrug resistance in microbes against antibiotics. The entry rate of antibiotics to the environment is much higher than its exclusion; therefore, efficient removal is a high priority to reduce the harmful impact of antibiotics on human health and the environment. Recent developments in cost-effective and efficient biochar preparation are noticeable for their effective removal. Moreover, biochar engineering advancements enhanced biochar remediation performance several folds more than in its pristine forms. Biochar engineering provides several new interactions and bonding abilities with antibiotic pollutants to increase remediation efficiency. Especially heteroatoms-doping significantly increased catalysis of biochar. The main focus of this review is to underline the crucial role of biochar in the abatement of emerging antibiotic pollutants. A detailed analysis of both native and engineered biochar is provided in this article for antibiotic remediation. There has also been discussion of how biochar properties relate to feedstock, production conditions and manufacturing technologies, and engineering techniques. It is possible to produce biochar with different surface functionalities by varying the feedstock or by modifying the pristine biochar with different chemicals and preparing composites. Subsequently, the interaction of biochar with antibiotic pollutants was compared and reviewed. Depending on the surface functionalities of biochar, they offer different types of interactions e.g., π-π stacking, electrostatic, and H-bonding to adsorb on the biochar surface. This review demonstrates how biochar and related composites have optimized for maximum removal performance by regulating key parameters. Furthermore, future research directions and opportunities for biochar research are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.